CDKN2A/p14ARF Antibody (YA8565)
(Synonyms: ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4)CDKN2A/p14ARF Antibody (YA8565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p14ARF.
-
Host:
Mouse
-
Isotype:
IgG1
-
Application:
IHC-P, FC
-
Reactivity :
Human
-
Formulation:
Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
-
Conjugation:
Non-conjugated
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
|---|---|---|
| Dilution Ratio | 1:2000-2500 | 1:100 |
Product Details
CDKN2A/p14ARF Antibody (YA8565) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CDKN2A/p14ARF.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 16.4 kDa
Full length human recombinant protein of human CDKN2A produced in E.coli.
Endogenous
Affinity purified
Non-conjugated
Unmodified
IgG1
Product Properties
-
Appearance
Liquid
-
Formulation
Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
CDKN2A/p14ARF is capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Plays a role in inhibiting ribosome biogenesis, perhaps by binding to the nucleolar localization sequence of transcription termination factor TTF1, and thereby preventing nucleolar localization of TTF1. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development|May be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP
-
Subcellular Localization
Nucleus, nucleolus,Nucleus, nucleoplasm,Mitochondrion
-
Isoforms & Post-Translational Modification
Q8N726 has 6 isomers: Q8N726-1: 13903 Da (predicted); P42771-1: 16533 Da (predicted); P42771-2: 11215 Da (predicted); P42771-3: 12083 Da (predicted); P42771-4: 17883 Da (predicted); Q8N726-2: 8731 Da (predicted).
Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardless of the absence of lysine residues -
Subunit
Does not interact with cyclins, CDK1, CDK2, CDK4, CDK5 or CDK6
-
SwissProt ID
-
Synonyms
ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4
Documentation